REVIEW PAPER
Treatment of systemic lupus erythematosus. Part II. The role of biologic agents
Online publication date: 2012-12-21
Reumatologia 2012;50(6):515-521
KEYWORDS
ABSTRACT
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology, characterized by multi-organ involvement, flares and complete or partial remission periods, resulted in increased morbidity and mortality. Symptomatic drugs, corticosteroids, antimalarial and immunosuppressive agents are effective in most of SLE patients. In patients with SLE resistant to conventional treatment new therapies must be considered. We present the role of biologic agents in the treatment of SLE, include currently used (belimumab and rituximab) and tested in clinical trials.
REFERENCES (35)
1.
Tsokos GC, Gordon C, Smolen JS. Systemic Lupus Erythematosus. Mosby Elsevier, 2007.
2.
Szmyrka-Kaczmarek M, Wiland P. Belimumab – nowe możliwości leczenia tocznia rumieniowatego układowego. Reumatologia 2012; 50: 349-351.
3.
Driver C, Ishimori M, Weisman M. The B cell in systemic lupus erythematosus: a rational target for more effective therapy. Ann Rheum Dis 2008; 67: 1374-1381.
4.
Bezalel S, Asher I, Elbirt D, et al. Novel biological treatments for systemic lupus erythematosus: current and future modalities. IMAJ 2012; 14: 508-514.
5.
Xiong W, Lahita R. Novel treatments for systemic lupus erythematosus. Ther Adv Musculoskel Dis 2011; 3: 255-266.
6.
Yildirim-Toruner C, Diamond B. Current and novel therapeutics in treatment of SLE. J Allergy Clin Immunol 2011; 127: 303-314.
7.
Wallace D. Advances in drug therapy for systemic lupus erythematosus. BMC Medicine 2010; 8: 77-81.
8.
Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233.
9.
Furie R, Looney RJ, Rovin B, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. ttp://acr.confex.com/acr/2009/webprogram/Paper12419. html.
10.
Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. ARD Online First, published on July 31, 2012 as 10.1136/annrheumdis-2012-201940.
11.
Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011; 20: 709-716.
12.
Jonsdottir T, Gunnarsson I, Risselada A, et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008; 67: 330-334.
13.
Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62: 2458-2466.
14.
Ng KP, Leandro MJ, Edwards JC, et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006; 65: 942-945.
15.
Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69: 2074-2082.
16.
Jonsdottir T, Gunnarsson I, Mourao AF, et al. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology (Oxford) 2010; 49: 1502-1504.
17.
Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Investig Drugs 2008; 9: 1206-1215.
18.
Epratuzumab Results in lupus presented at 2012 Annual European Congress of Rheumatology. http://www.globenewswire.com /news-release/2012/06/08/478941/258673/en/Epratuzumab-Results-in-Lupus-Presented-at-2012-Annual-European-Congress-of-Rheumatology.html.
19.
Navarra SV, Guzman RM, Gallacher AE, et al. for the BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-731.
20.
Furie R, Petri M, Zamani O, et al. for the BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-3930.
22.
van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012; doi: 10.1136/annrheumdis-2011-200937.
23.
Dooley MA, Houssiau F, Aranow C, et al.; and BLISS-52/-76 Study Groups. Effect of belimumab treatment on renal outcomes: results from phase 3 belimumab clinical trials in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63 (Suppl): abstract 2472.
24.
Ginzler E, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012; 14: 33-39.
25.
Dall’Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus. Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56: 4142-4150.
26.
La Cava A. Anticytokine therapies in systemic lupus erythematosus. Immunotherapy 2010; 2: 575-582.
27.
Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 3077-3087.
29.
Ponticelli C, Moroni G. Monoclonal antibodies for systemic lupus erythematosus. Pharmaceuticals 2010; 3: 300-322.
30.
Aringer M, Graninger W, Steiner G, et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004; 50: 3161-3169.
31.
Aringer M, Smolen J. Efficacy and safety of TNF-βlocker therapy in systemic lupus erythematosus. Expert Opin Drug Saf 2008; 7: 411-419.
32.
Merrill J, Wallace D, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicenter, double-blind randomized study. Ann Rheum Dis 2011; 70: 1905-1913.
33.
Merrill J, Chindalore V, Box J, et al. Results of a randomized, placebo-controlled, phase 2a study of sifalimumab, an anti-interferon-alpha monoclonal antibody, administered subcutaneously in subject with systemic lupus erythematosus. http://www.abstracts2view.com/....
34.
McBride J, Jiang J, Abbas A, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 2012; 64: 3666-3676.
35.
Illei G, Shirota Y, Yarboro C, et al. Tocilizumab in systemic lupus erythematosus- safety, preliminary efficacy, and impact on circulating plasma cells. Arthritis Rheum 2010; 62: 542-552.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
